Pre-Made Oportuzumab Monatox biosimilar, Fusion Protein, Oportuzumab-Anti-EPCAM Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibody fused with Pseudomonas aeruginosa exotoxin A for drug discovery and mechanism of action (MOA) research

Pre-Made Oportuzumab Monatox biosimilar, Fusion Protein, Oportuzumab-Anti-EPCAM Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibody fused with Pseudomonas aeruginosa exotoxin A is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Oportuzumab monatox (proposed INN, trade name Vicineum) is an antineoplastic. Chemically, oportuzumab is a single chain variable fragment of a monoclonal antibody which binds to epithelial cell adhesion molecule (EpCAM, the tumor-associated calcium signal transducer 1). Oportuzumab is fused with Pseudomonas aeruginosa exotoxin A (which is reflected by the monatox in the drug's name).[1]

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-INN-939-1mg	1mg	3090
GMP-Bios-INN-939-10mg	10mg	Inquiry
GMP-Bios-INN-939-100mg	100mg	Inquiry
GMP-Bios-INN-939-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Oportuzumab Monatox biosimilar, Fusion Protein, Oportuzumab-Anti-EPCAM Antibody: Anti-Ber-Ep4/BerEp4/DIAR5/EGP-2/EGP314/EGP40/ESA/HNPCC8/KS1/4/KSA/M4S1/MIC18/MK-1/MOC-31/TACSTD1/TROP1 therapeutic antibody fused with Pseudomonas aeruginosa exotoxin A
INN Name	Oportuzumab Monatox
Target	EPCAM
Format	Fusion Protein
Derivation	Humanized
Species Reactivity	human
CH1 Isotype	scFv - kappa - heavy
VD LC	scFv - kappa - heavy
Highest_Clin_Trial (Jan '20)
Est. Status
100% SI Structure
99% SI Structure
95-98% SI Structure
Year Proposed
Year Recommended
Companies	Viventia Biotechnologies Inc. (Mississauga ON Canada)
Conditions Approved
Conditions Active
Conditions Discontinued
Development Tech	0